Oxaliplatin plus leucovorin and 5-fluorouracil (FOLFOX-4) as a salvage chemotherapy in heavily-pretreated platinum-resistant ovarian cancer

Vincenza Conteduca,Giorgia Gurioli,Lorena Rossi,Emanuela Scarpi,Cristian Lolli,Giuseppe Schepisi,Alberto Farolfi,Delia De Lisi,Valentina Gallà,Salvatore Luca Burgio,Cecilia Menna,Andrea Amadori,Lorena Losi,Dino Amadori,Maria Paola Costi,Ugo De Giorgi

Oxaliplatin plus leucovorin and 5-fluorouracil (FOLFOX-4) as a salvage chemotherapy in heavily-pretreated platinum-resistant ovarian cancer

2018

Vincenza Conteduca
Giorgia Gurioli
Lorena Rossi
Emanuela Scarpi
Cristian Lolli
Giuseppe Schepisi
Alberto Farolfi
Delia De Lisi
Valentina Gallà
Salvatore Luca Burgio
Cecilia Menna
Andrea Amadori
Lorena Losi
Dino Amadori
Maria Paola Costi
Ugo De Giorgi

Background The purpose of this study was to evaluate the clinical impact of oxaliplatin, leucovorin, and 5-fluorouracil (FOLFOX-4) chemotherapy in terms of the response rate, progression-free/overall survival (PFS/OS) and safety profile in patients with heavily pretreated recurrent epithelial ovarian cancer.

Keywords:

Ovarian cancer
Cancer research
Medicine
Topotecan
Fluorouracil
FOLFOX
Surgical oncology
Oxaliplatin
Internal medicine
Oncology
Chemotherapy
salvage treatment

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations